Vis enkel innførsel

dc.contributor.authorvon Bülow, Anna
dc.contributor.authorHansen, Susanne
dc.contributor.authorSandin, Patrik
dc.contributor.authorErnstsson, Olivia
dc.contributor.authorJanson, Christer
dc.contributor.authorLehtimäki, Lauri
dc.contributor.authorKankaanranta, Hannu
dc.contributor.authorUlrik, Charlotte
dc.contributor.authorAarli, Bernt Bøgvald
dc.contributor.authorGeale, Kirk
dc.contributor.authorTang, Sheila Tuyet
dc.contributor.authorWolf, Maija
dc.contributor.authorBacker, Vibeke
dc.contributor.authorHilberg, Ole
dc.contributor.authorAltraja, Alan
dc.contributor.authorBackman, Helena
dc.contributor.authorLudviksdottir, Dora
dc.contributor.authorBjörnsdottir, Unnur Steina
dc.contributor.authorKauppi, Paula
dc.contributor.authorSandström, Thomas
dc.contributor.authorSverrild, Asger
dc.contributor.authorYasinska, Valentyna
dc.contributor.authorKilpeläinen, Maritta
dc.contributor.authorDahlen, Barbro
dc.contributor.authorViinanen, Arja
dc.contributor.authorBjermer, Leif
dc.contributor.authorBossios, Apostolos
dc.contributor.authorPorsbjerg, Celeste
dc.date.accessioned2023-09-19T11:44:51Z
dc.date.available2023-09-19T11:44:51Z
dc.date.created2023-09-15T15:17:28Z
dc.date.issued2023
dc.identifier.issn0903-1936
dc.identifier.urihttps://hdl.handle.net/11250/3090429
dc.description.abstractBackground There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma. Methods We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018. Results Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of severe asthma that were labelled as: trajectory 1 “consistently severe asthma” (n=389 (8.6%)), trajectory 2 “gradual onset severe asthma” (n=942 (20.7%)), trajectory 3 “intermittent severe asthma” (n=1685 (37.1%)) and trajectory 4 “sudden onset severe asthma” (n=1527 (33.6%)). “Consistently severe asthma” had a higher daily inhaled corticosteroid dose and more prevalent osteoporosis compared with the other trajectories. Patients with “gradual onset severe asthma” and “sudden onset severe asthma” developed type 2-related comorbidities concomitantly with development of severe asthma. In the latter group, this primarily occurred within 1–3 years preceding onset of severe asthma. Conclusions Four distinct trajectories of severe asthma were identified illustrating different patterns of progression of asthma severity. This may eventually enable the development of better preventive management strategies in severe asthma.en_US
dc.language.isoengen_US
dc.publisherERSen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleSevere asthma trajectories in adults: findings from the NORDSTAR cohorten_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber2202474en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1183/13993003.02474-2022
dc.identifier.cristin2175545
dc.source.journalEuropean Respiratory Journalen_US
dc.identifier.citationEuropean Respiratory Journal. 2023, 62, 2202474.en_US
dc.source.volume62en_US
dc.source.issue3en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal